Literature DB >> 25052075

Portopulmonary hypertension: improved detection using CT and echocardiography in combination.

Anand Devaraj1, Robert Loveridge, Diana Bosanac, Konstantinos Stefanidis, William Bernal, Christopher Willars, Julia A Wendon, Georg Auzinger, Sujal R Desai.   

Abstract

OBJECTIVES: To establish the relationship between CT signs of pulmonary hypertension and mean pulmonary artery pressure (mPAP) in patients with liver disease, and to determine the additive value of CT in the detection of portopulmonary hypertension in combination with transthoracic echocardiography.
METHODS: Forty-nine patients referred for liver transplantation were retrospectively reviewed. Measured CT signs included the main pulmonary artery/ascending aorta diameter ratio (PA/AAmeas) and the mean left and right main PA diameter (RLPAmeas). Enlargement of the pulmonary artery compared to the ascending aorta was also assessed visually (PA/AAvis). CT measurements were correlated with right-sided heart catheter-derived mPAP. The ability of PA/AAvis combined with echocardiogram-derived right ventricular systolic pressure (RVSP) to detect portopulmonary hypertension was tested with ROC analysis.
RESULTS: There were moderate correlations between mPAP and both PA/AAmeas and RLPAmeas (rs = 0.41 and rs = 0.42, respectively; p < 0.005). Compared to transthoracic echocardiography alone (AUC = 0.59, p = 0.23), a diagnostic algorithm incorporating PA/AAvis and transthoracic echocardiography-derived RVSP improved the detection of portopulmonary hypertension (AUC = 0.8, p < 0.0001).
CONCLUSIONS: CT contributes to the non-invasive detection of portopulmonary hypertension when used in a diagnostic algorithm with transthoracic echocardiography. CT may have a role in the pre-liver transplantation triage of patients with portopulmonary hypertension for right-sided heart catheterisation. KEY POINTS: • CT signs correlate with right-sided heart catheter data in portopulmonary hypertensionCT adds to the transthoracic echocardiography detection of portopulmonary hypertensionCT may have a complementary role in pre-liver transplantation triage.

Entities:  

Mesh:

Year:  2014        PMID: 25052075     DOI: 10.1007/s00330-014-3289-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

1.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

Review 2.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

3.  Computed tomographic screening of pulmonary arterial hypertension in candidates for lung transplantation.

Authors:  D Pérez-Enguix; P Morales; J M Tomás; F Vera; R M Lloret
Journal:  Transplant Proc       Date:  2007-09       Impact factor: 1.066

4.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

5.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

Review 6.  Portopulmonary hypertension.

Authors:  Michael J Krowka
Journal:  Semin Respir Crit Care Med       Date:  2012-03-23       Impact factor: 3.119

7.  CT measurement of main pulmonary artery diameter.

Authors:  P D Edwards; R K Bull; R Coulden
Journal:  Br J Radiol       Date:  1998-10       Impact factor: 3.039

Review 8.  Screen for portopulmonary hypertension, especially in liver transplant candidates.

Authors:  Karen L Swanson; Michael J Krowka
Journal:  Cleve Clin J Med       Date:  2008-02       Impact factor: 2.321

9.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 10.  Cardiac causes of pulmonary arterial hypertension: assessment with multidetector CT.

Authors:  Edward T D Hoey; Deepa Gopalan; S K Bobby Agrawal; Nicholas J Screaton
Journal:  Eur Radiol       Date:  2009-05-27       Impact factor: 5.315

View more
  2 in total

1.  Pulmonary hypertension due to left heart disease: diagnostic and prognostic value of CT in chronic systolic heart failure.

Authors:  Geoffrey C Colin; Bernhard L Gerber; Christophe de Meester de Ravenstein; David Byl; Anna Dietz; Michele Kamga; Agnes Pasquet; David Vancraeynest; Jean-Louis Vanoverschelde; Anne-Marie D'Hondt; Benoit Ghaye; Anne-Catherine Pouleur
Journal:  Eur Radiol       Date:  2018-05-14       Impact factor: 5.315

2.  Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: a meta-analysis.

Authors:  Xin Yin; Yueming Shao; Yu Zhang; Hui Gao; Tingting Qin; Xiaoyu Wen; Chen Yang
Journal:  PeerJ       Date:  2020-05-27       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.